1875 — TOT Biopharm International Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.30bn
- HK$1.29bn
- CNY780.63m
- 22
- 28
- 39
- 15
Annual cashflow statement for TOT Biopharm International Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -299 | -288 | -261 | -50 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 53.6 | 12.9 | 11.8 | 28.5 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -33 | -19.6 | 40 | 43.4 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -251 | -263 | -175 | 59.9 | — |
| Capital Expenditures | -37.3 | -22.2 | -115 | -240 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -13.8 | 34.7 | 6.92 | -42.6 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -51.1 | 12.5 | -108 | -283 | — |
| Financing Cash Flow Items | -16.8 | 0 | 5.62 | 402 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 583 | -61.7 | 212 | 481 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 282 | -314 | -72.7 | 265 | — |